정밀의료 시장 : 시장 규모, 점유율, 동향 및 예측 - 제품별, 기술별, 용도별, 최종 사용자별, 지역별(2026-2034년)

The global precision medicine market size reached USD 89.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 186.3 Billion by 2034, exhibiting a growth rate (CAGR) of 8.28% during 2026-2034. Significant advancements in genomics, increasing healthcare personalization, rising prevalence of chronic diseases, technological innovations, growing investment in research, and a shift towards more effective, tailored treatments are influencing the precision medicine industry.

Precision Medicine Market Analysis:

• Market Growth and Size: The precision medicine market share is experiencing rapid growth, driven by increasing demand for personalized treatment modalities and advancements in genomic science. Precision medicine market trends are reflected in the expanding range of precision medicine applications and the significant investments flowing into the sector.
• Major Market Drivers: Key drivers include technological advancements in genomics, the rising prevalence of chronic diseases, a shift towards personalized healthcare, and substantial investments in research and development (R&D). These factors are collectively propelling the market forward, aligning with the growing emphasis on more effective and tailored healthcare solutions.
• Technological Advancements: Innovations in gene sequencing, big data analytics, and bioinformatics are pivotal, enabling the detailed analysis of genetic data, which in turn facilitates personalized treatment strategies. Such technological progress is vital for the development of targeted therapies and precision diagnostic tools.
• Industry Applications: Precision medicine finds extensive applications across oncology, central nervous system (CNS) disorders, immunology, and respiratory medicine, among others, where it enables tailored therapeutic strategies, leading to improved patient outcomes and more efficient disease management.
• Key Market Trends: Some of the key precision medicine market trends include the integration of artificial intelligence (AI) and machine learning (ML) to enhance the predictive power of genetic data and improve the personalization of patient care. The market is also seeing a rise in companion diagnostics, emphasizing the importance of aligning therapeutic decisions with individual genetic information.
• Geographical Trends: North America leads the market, supported by advanced healthcare infrastructure and significant healthcare investments. However, Asia Pacific is rapidly growing due to increasing healthcare awareness, investment in healthcare infrastructure, and governmental support for personalized medicine.
• Competitive Landscape: The market is highly competitive, with key players focusing on innovation, strategic partnerships, and expanding their product portfolios to include sophisticated precision medicine solutions. The competitive edge is largely defined by technological innovation, regulatory approvals, and market expansion strategies.
• Challenges and Opportunities: Challenges include high costs, complex regulatory environments, and the need for extensive data integration. On the other hand, these challenges present opportunities for innovation in cost reduction, regulatory strategy optimization, and the development of advanced data analytics to enhance the efficacy and accessibility of precision medicine.

Precision Medicine Market Trends:

Technological advancements in genomics and bioinformatics

One of the most significant drivers driving the precision medicine market growth is the rapid advancement in genomics and bioinformatics. High-throughput sequencing technologies have made genome sequencing faster and more affordable, enabling the widespread use of genomic information in clinical practice. This has led to the development of personalized treatments based on the genetic makeup of individuals. Moreover, bioinformatics, which combines biological data with statistical analysis and computational tools, plays a crucial role in interpreting the vast amounts of data generated by genomic sequencing. These technological advancements have paved the way for the identification of genetic mutations responsible for various diseases and the development of targeted therapies that improve treatment outcomes, boosting precision medicine market share.

Increasing prevalence of chronic diseases

The global increase in chronic diseases such as cancer, diabetes, and cardiovascular diseases (CVDs) is one of the crucial precision medicine market trends aiding in market expansion. These conditions are leading causes of death and disability worldwide, placing a significant burden on healthcare systems. Precision medicine offers a promising approach to managing these diseases, with targeted therapies designed to treat each patient's disease based on their unique genetic profile. This personalized approach not only improves the effectiveness of treatment but also reduces the risk of adverse drug reactions, thereby enhancing patient outcomes and reducing healthcare costs. As the prevalence of these diseases continues to rise, the demand for precision medicine approaches is expected to grow, driving the precision medicine market growth.

Growing investment in research and development

Investment in research and development (R&D) in the precision medicine industry is acting as another significant growth-inducing factor. Governments, private entities, and philanthropic organizations are increasingly funding R&D activities in precision medicine to uncover novel therapeutic targets and develop new diagnostic tools and treatments. This investment is crucial for the continuous discovery of biomarkers, the development of companion diagnostics, and the advancement of personalized therapies. Such financial support is fueling innovations in the pipeline and accelerating the translation of scientific discoveries into clinical applications, thereby fostering the growth of the precision medicine share.

Shift Towards Personalized Healthcare

The growing shift towards personalized healthcare, driven by the increasing demand for tailored treatment options and the rising emphasis on preventive medicine is bolstering the precision medicine market growth. Patients and healthcare providers are becoming more aware of the benefits of personalized medicine, such as improved treatment efficacy, minimized trial and error in drug selection, and reduced treatment costs in the long run. This shift is supported by the integration of electronic health records (EHRs) with genomic data, which enhances the ability to tailor medical treatment to individual characteristics. As a result, there is a growing demand for precision medicine solutions, which is expected to boost precision medicine market share.

Precision Medicine Industry Segmentation:

Breakup by Product:

• Consumables
• Instruments
• Services

The growing demand for precision medicine consumables, driven by the recurring need for new reagents and assays in personalized treatment protocols to ensure ongoing precision in patient-specific diagnostic and therapeutic processes is influencing the precision medicine industry.

Besides this, the surge in demand for precision medicine instruments owing to their critical role in advanced diagnostics and therapeutic monitoring, facilitating high-precision, real-time data for personalized healthcare decisions is aiding in market expansion.

Concurrently, the increasing reliance on precision medicine services is fueled by the necessity for expert analysis, interpretation of complex genomic data, and the customization of therapy plans, enhancing the efficacy of personalized treatment strategies.

Breakup by Technology:

• Big Data Analytics
• Bioinformatics
• Gene Sequencing
• Drug Discovery
• Companion Diagnostics
• Others

Drug discovery holds the largest share in the market

The demand for precision medicine in drug discovery is mainly propelled by the necessity to develop more effective, safer medications tailored to individual genetic profiles. This approach leverages high-throughput genomic technologies and bioinformatics, enabling researchers to identify novel therapeutic targets and predict drug responses more accurately. It also facilitates the creation of targeted therapies that significantly improve patient outcomes, reduce adverse effects, and expedite the journey from laboratory research to clinical practice, thus creating a favorable outlook for market expansion.

In line with this, the integration of big data analytics in the healthcare sector for deciphering complex datasets, enabling predictive modeling and personalized treatment strategies is positively impacting the precision medicine industry.

Moreover, the rising demand for bioinformatics, essential in precision medicine for analyzing biological data, especially in understanding genetic variations, which facilitates personalized therapeutic strategies and enhances diagnostic accuracy is impelling the market growth.

In confluence with this, gene sequencing technology is fundamental in identifying genetic disorders and tailoring individualized treatments, which is contributing to its expanding demand in the development of precision medicine.

Additionally, the growing use of companion diagnostics for the effective implementation of precision medicine is aiding in market expansion, as they enable the identification of patients likely to benefit from specific treatments, ensuring targeted therapeutic approaches.

Apart from this, emerging technologies like clustered regularly interspaced short palindromic repeats (CRISPR) gene editing and AI-driven predictive models are propelling precision medicine by enabling groundbreaking personalized treatments and advancing our understanding of complex diseases.

Breakup by Application:

• Oncology
• Central Nervous System (CNS)
• Immunology
• Respiratory Medicine
• Infections
• Others

Oncology holds the largest share in the market

The demand for precision medicine in oncology is driven by its potential to revolutionize cancer treatment through personalized therapy. By understanding the genetic mutations and molecular characteristics of individual tumors, precision oncology allows for the development of targeted therapies that are more effective and have fewer side effects than traditional treatments. This tailored approach improves patient outcomes, enhances survival rates, and offers hope for those with previously untreatable cancers.

In addition to this, precision medicine also finds extensive applications in CNS disorders due to its potential to tailor treatments for neurological conditions, enhancing efficacy and reducing side effects tailored to individual genetic profiles.

Furthermore, immunology's growing reliance on precision medicine due to its ability to customize immune therapies, thereby improving treatment outcomes for autoimmune diseases by targeting patient-specific immunological pathways is fueling the market growth.

In confluence with this, the push for precision medicine in respiratory medicine for its capacity to personalize therapies for chronic respiratory diseases, optimizing treatment effectiveness and patient management based on individual genetic variations is fostering market expansion.

Moreover, the increasing demand in infections, driven by the precision medicine approach to develop targeted antimicrobial treatments to effectively combat antibiotic-resistant strains and tailored therapy based on the pathogen's genetic makeup is influencing market growth.

Besides this, precision medicine is also gaining traction for its ability to provide customized solutions across various medical fields, enhancing treatment precision, improving clinical outcomes, and offering novel therapeutic options tailored to individual patient profiles.

Breakup by End User:

• Hospitals and Clinics
• Diagnostic Centers
• Pharma and Biotech Companies
• Healthcare IT Firms
• Others

Hospitals and clinics hold the largest share in the market

The demand for precision medicine in hospitals and clinics is escalating as these settings increasingly recognize its potential to significantly enhance patient care. By integrating individual genetic information, hospitals and clinics can offer more accurate diagnoses, effective treatments, and personalized care plans. This shift not only improves patient outcomes but also optimizes healthcare resources, reduces hospitalization rates, and tailors patient management, aligning with the evolving expectations of personalized healthcare.

Along with this, the growing need for precise, personalized diagnostic information to facilitate targeted treatment plans and improved patient outcomes is boosting the adoption of precision medicine approaches in diagnostic centers.

Moreover, pharma and biotech companies are increasingly investing in precision medicine to develop targeted therapies that offer higher efficacy and reduced risk, tailoring treatments to individual genetic profiles, which is further impelling the market growth.

In line with this, healthcare information technology (IT) firms play a pivotal role in advancing precision medicine, providing the data management and analytics capabilities essential for interpreting complex genomic data and supporting personalized healthcare solutions.

Other sectors, including research institutions and academic centers, are further boosting the demand for precision medicine by pioneering innovative approaches and technologies that enable personalized treatment strategies and advance the field of individualized care.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest precision medicine market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America's robust healthcare infrastructure, substantial investments in healthcare technology, and a strong emphasis on research and innovation are presenting lucrative opportunities for market expansion. The region's advanced regulatory framework supports the rapid adoption of personalized therapies, while the presence of leading biotech and pharmaceutical companies is fueling continuous advancements in precision medicine. Additionally, the presence of a well-informed population with increasing healthcare expectations is further providing an impetus to the market growth.

Besides this, the strong governmental support in Europe, extensive research collaborations, and well-established healthcare systems prioritizing personalized healthcare solutions and innovation in precision medicine are aiding in market expansion.

Concurrently, rapidly growing healthcare infrastructure, increasing investments in biotechnology, and rising awareness of personalized medicine's benefits are fueling the demand in the Asia Pacific region.

Furthermore, In Latin America, growing healthcare expenditure, increasing focus on research and development, and the rising prevalence of chronic diseases are boosting the adoption of precision medicine.

Apart from this, the demand in the Middle East and Africa is propelled by increasing healthcare investments, government initiatives to incorporate advanced healthcare technologies, and the rising demand for effective, personalized therapeutic approaches.

Leading Key Players in the Precision Medicine Industry:

The competitive landscape of the global precision medicine market is intensely dynamic and characterized by rapid technological advancements, strategic collaborations, and a strong focus on innovation. Major players in the field, including biotechnology firms, pharmaceutical giants, and healthcare IT companies, are continually expanding their product portfolios and enhancing their capabilities through research and development (R&D) investments, mergers and acquisitions, and partnerships with academic institutions and research organizations. These companies are competing fiercely to develop and commercialize precision medicine solutions that include advanced genomic analysis, biomarker detection, and personalized therapeutic interventions. The market is also witnessing a growing emphasis on regulatory compliance and the establishment of robust intellectual property rights, which are crucial for sustaining competitive advantage.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• AstraZeneca plc
• Bayer AG
• bioMerieux SA
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Illumina Inc.
• Laboratory Corporation of America Holdings
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Qiagen N.V.
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific Inc.

Frequently Asked Questions About the Precision Medicine Market Size Report

1.How big is the precision medicine market?

2.What is the future outlook for the precision medicine market?

3.What are the key factors driving the precision medicine market?

4.Which region accounts for the largest precision medicine market share?

5.Which are the leading companies in the global precision medicine market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Precision Medicine Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Consumables
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Instruments
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Services
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Big Data Analytics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Bioinformatics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Gene Sequencing
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Drug Discovery
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Companion Diagnostics
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Application

• 8.1 Oncology
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Central Nervous System (CNS)
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Immunology
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Respiratory Medicine
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Infections
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Others
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospitals and Clinics
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Diagnostic Centers
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Pharma and Biotech Companies
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Healthcare IT Firms
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Others
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 AstraZeneca plc
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Bayer AG
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 bioMerieux SA
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Bristol-Myers Squibb Company
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Eli Lilly and Company
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 F. Hoffmann-La Roche AG
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 SWOT Analysis
  • 15.3.7 Illumina Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Laboratory Corporation of America Holdings
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Merck KGaA
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Novartis AG
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Pfizer Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Qiagen N.V.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis
  • 15.3.13 Quest Diagnostics Incorporated
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio
    • 15.3.13.3 Financials
    • 15.3.13.4 SWOT Analysis
  • 15.3.14 Thermo Fisher Scientific Inc.
    • 15.3.14.1 Company Overview
    • 15.3.14.2 Product Portfolio
    • 15.3.14.3 Financials
    • 15.3.14.4 SWOT Analysis